Dr.Reddy’s launches anti-cancer injection in US market

Views: 998

Dr.Reddy’s Laboratories (DRL)  has launched anti-cancer injection in the United States market.

Dr. Reddy’s Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection has been approved by the US Food and Drug Administration (USFDA), DRL said in a statement.

The drug contains one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.

The Alkeran brand and generic had US sales of approximately USD 107 million MAT ( Moving Auula Turnover) in the last 12 months ending October 2017.

The drug  should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.

Most Popular





Get Heard Portal


eHealth Event Report




About Us

eHEALTH, as an online and print platform, elegantly guides the healthcare stakeholders through the trajectory of healthcare that witnesses fascinating changes on a daily basis due to increased technological intervention and other structural changes to create a ‘community of practice’ of healthcare stakeholders.


Contact Us

Elets Technomedia Pvt. Ltd.
Stellar IT Park, Office No. 7A/7B, 5th Floor, Tower -2 Annexe Building, C-25, Sector 62 Noida, Uttar Pradesh - 201309, India

Copyright © 2018 Elets | All rights reserved

To Top